Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 17 Parkinson's papers of 1,297 | 0.62 |
| pathways Reactome | 3 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 5587
Sealed predictions
- NR4A1 in dopamine neurons, braak-0.50 (p 0.173) → -0.33 (p 0.387)receipt 5594
Swarm cases
receipt 5594: NR4A1 in dopamine neurons, braak
- power
- full sample -0.51 (p 0.029, n 18), 95% CI -0.79 to -0.06. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.50 (p 0.036, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.027, n 18). not the mix.
- skeptic
- leave-one-out range -0.62 to -0.45, sign flips 0; without severely affected donors -0.51 (p 0.029, n 18). robust.
- cell type
- strongest in astrocytes: -0.60 (p 0.0083, n 18) vs -0.51 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NR4A1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NR4A1 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.10 p 0.722 (needs p < 3.6e-4)
Receipts
loading the receipts